Differential management of mild-to-severe psoriasis with biologic drugs : An Italian Delphi consensus expert panel
BACKGROUND: In the management of moderate-to-severe psoriasis, increasingly complex clinical scenarios necessitate practical tools for appropriate biologic therapy selection in individual patients. An Italian Delphi consensus panel provided guidance on biologic use in selected clinical scenarios.
METHODS: Ten experts defined statements under consideration, which were distributed as an online survey to a dermatologist panel. Plenary discussions of contentious statements were held to achieve consensus.
RESULTS: The survey was sent to 30 clinicians. After plenary discussions, consensus was reached on all 20 statements on the following topics: special populations; infections; comorbidities; immunogenicity; extra-cutaneous involvement; pregnancy; and adherence. Three statements required further discussion in order to gain consensus: use of subcutaneous biologics in mild liver impairment (final 94% agreement), use of any biologic in discoid lupus erythematosus (final 100% disagreement), and use of etanercept in patients with history of hypersensitivity reactions to drugs and/or food (final 75% disagreement).
CONCLUSIONS: This Delphi expert consensus on the use of biologics in psoriasis provides practical recommendations for dermatologists to use when choosing an appropriate biologic in challenging but common clinical scenarios. More data are required to clarify clinical differences of biologic drugs used to treat psoriasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
The Journal of dermatological treatment - 26(2015), 2 vom: 06. Apr., Seite 128-33 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Girolomoni, Giampiero [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 22.12.2015 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3109/09546634.2014.907466 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM23713473X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM23713473X | ||
| 003 | DE-627 | ||
| 005 | 20231224111024.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3109/09546634.2014.907466 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0790.xml |
| 035 | |a (DE-627)NLM23713473X | ||
| 035 | |a (NLM)24708158 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Girolomoni, Giampiero |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differential management of mild-to-severe psoriasis with biologic drugs |b An Italian Delphi consensus expert panel |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2015 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: In the management of moderate-to-severe psoriasis, increasingly complex clinical scenarios necessitate practical tools for appropriate biologic therapy selection in individual patients. An Italian Delphi consensus panel provided guidance on biologic use in selected clinical scenarios | ||
| 520 | |a METHODS: Ten experts defined statements under consideration, which were distributed as an online survey to a dermatologist panel. Plenary discussions of contentious statements were held to achieve consensus | ||
| 520 | |a RESULTS: The survey was sent to 30 clinicians. After plenary discussions, consensus was reached on all 20 statements on the following topics: special populations; infections; comorbidities; immunogenicity; extra-cutaneous involvement; pregnancy; and adherence. Three statements required further discussion in order to gain consensus: use of subcutaneous biologics in mild liver impairment (final 94% agreement), use of any biologic in discoid lupus erythematosus (final 100% disagreement), and use of etanercept in patients with history of hypersensitivity reactions to drugs and/or food (final 75% disagreement) | ||
| 520 | |a CONCLUSIONS: This Delphi expert consensus on the use of biologics in psoriasis provides practical recommendations for dermatologists to use when choosing an appropriate biologic in challenging but common clinical scenarios. More data are required to clarify clinical differences of biologic drugs used to treat psoriasis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Clinical recommendations | |
| 650 | 4 | |a survey | |
| 650 | 4 | |a treatment choice | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Etanercept |2 NLM | |
| 650 | 7 | |a OP401G7OJC |2 NLM | |
| 700 | 1 | |a Altomare, Gianfranco |e verfasserin |4 aut | |
| 700 | 1 | |a Ayala, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Berardesca, Enzo |e verfasserin |4 aut | |
| 700 | 1 | |a Calzavara Pinton, Piergiacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Chimenti, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Martini, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Peserico, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Puglisi Guerra, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Vena, Gino Antonio |e verfasserin |4 aut | |
| 700 | 0 | |a Delphi working group |e verfasserin |4 aut | |
| 700 | 1 | |a Altomare, A |e investigator |4 oth | |
| 700 | 1 | |a Ardigò, M |e investigator |4 oth | |
| 700 | 1 | |a Balato, N |e investigator |4 oth | |
| 700 | 1 | |a Bonifati, C |e investigator |4 oth | |
| 700 | 1 | |a Borroni, G |e investigator |4 oth | |
| 700 | 1 | |a Brunetti, B |e investigator |4 oth | |
| 700 | 1 | |a Cassano, N |e investigator |4 oth | |
| 700 | 1 | |a Congedo, M |e investigator |4 oth | |
| 700 | 1 | |a Cusano, N |e investigator |4 oth | |
| 700 | 1 | |a Del Giglio, M |e investigator |4 oth | |
| 700 | 1 | |a Di Lernia, V |e investigator |4 oth | |
| 700 | 1 | |a Diguseppe, D |e investigator |4 oth | |
| 700 | 1 | |a Esposito, M |e investigator |4 oth | |
| 700 | 1 | |a Fantini, F |e investigator |4 oth | |
| 700 | 1 | |a Franchi, C |e investigator |4 oth | |
| 700 | 1 | |a Frigerio, E |e investigator |4 oth | |
| 700 | 1 | |a Loconsole, F |e investigator |4 oth | |
| 700 | 1 | |a Maiani, E |e investigator |4 oth | |
| 700 | 1 | |a Malara, G |e investigator |4 oth | |
| 700 | 1 | |a Massimino, D |e investigator |4 oth | |
| 700 | 1 | |a Mazzotta, A M |e investigator |4 oth | |
| 700 | 1 | |a Papagrikoraki, A |e investigator |4 oth | |
| 700 | 1 | |a Perona, A |e investigator |4 oth | |
| 700 | 1 | |a Piaserico, S |e investigator |4 oth | |
| 700 | 1 | |a Schipani, K |e investigator |4 oth | |
| 700 | 1 | |a Sirna, R |e investigator |4 oth | |
| 700 | 1 | |a Stan, R |e investigator |4 oth | |
| 700 | 1 | |a Todaro, F |e investigator |4 oth | |
| 700 | 1 | |a Zanca, A |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of dermatological treatment |d 1992 |g 26(2015), 2 vom: 06. Apr., Seite 128-33 |w (DE-627)NLM088851680 |x 1471-1753 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2015 |g number:2 |g day:06 |g month:04 |g pages:128-33 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3109/09546634.2014.907466 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2015 |e 2 |b 06 |c 04 |h 128-33 | ||